Preclinical Data Presented at the 2024
EORTC-NCI-AACR Symposium on Molecular Targets and
Cancer Therapeutics
AUSTIN, Texas , Oct. 28,
2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or
the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy
company focused on developing life-changing therapies for patients
with cancer and diabetes, today announced that research
collaborators delivered poster presentations at the 2024
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics held October 23-25, 2024
in Barcelona, Spain. The
collaborators presented posters on positive preclinical data from
studies of Genprex's lead drug candidate, Reqorsa® Gene Therapy
(quaratusugene ozeplasmid), for the treatment of Ras inhibitor
resistant lung cancer, mesothelioma and glioblastoma.
"We are pleased by this promising preclinical data, presented
before a prestigious audience of oncology researchers, of REQORSA's
potential in serious and difficult to treat cancers including KRAS
G12C mutant lung cancer, mesothelioma, and glioblastoma," said
Ryan Confer, President and Chief
Executive Officer at Genprex. "The role of TUSC2 in lung cancer has
been well established, and TUSC2 restoration is being evaluated
clinically. However, we are highly encouraged by our preclinical
programs expanding the potential use of REQORSA to treat a variety
of cancer indications, where patient populations have unmet medical
needs."
Genprex has filed two provisional patent applications based on
data from two of the presentations. One application involves using
REQORSA to treat mesothelioma and the other uses REQORSA to treat
glioblastoma. Genprex is a co-owner of the applications along with
the respective institutions. TUSC2 is the tumor suppressor gene
used in REQORSA. Last month, Genprex announced the formation of its
Mesothelioma Clinical Advisory Board to support the Company's
preclinical mesothelioma oncology program. The Board is comprised
of four world-renown researchers from major research institutions
specializing in the treatment of mesothelioma.
Featured Genprex-supported posters presented at the 2024
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics include:
Title: "TUSC2 Gene Therapy in KRASG12C
Mutant NSCLC Overcomes Acquired Resistance to Sotorasib"
Collaborator: The University of
Texas MD Anderson Cancer Center
Catalog Number: 384
Presentation Number: PB372
Title: "TUSC2 Suppresses Tumorigenic Properties in
Malignant Pleural Mesothelioma Cells"
Collaborator: New York
University Langone Health
Catalog Number: 364
Presentation Number: PB352
Title: "Efficacy of Quaratusugene Ozeplasmid (REQORSA)
TUSC2 Gene Therapy in Glioblastoma"
Collaborator: The University of Texas
Health Science Center at Houston
Catalog Number: 130
Presentation Number: PB118
To review the posters in detail, please visit Genprex's website,
where they are available to download.
About Reqorsa® Gene Therapy
REQORSA (quaratusugene
ozeplasmid) consists of a plasmid containing the TUSC2 gene
encapsulated in non-viral lipid-based nanoparticles in
a lipoplex form (the Company's Oncoprex® Delivery
System), which has a positive charge. REQORSA is injected
intravenously and specifically targets cancer cells. REQORSA is
designed to deliver the functioning TUSC2 gene to negatively
charged cancer cells while minimizing uptake by normal tissue.
Laboratory studies conducted at MD Anderson show that the
uptake of TUSC2 in tumor cells in vitro after REQORSA treatment
was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex's technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. Genprex's oncology program
utilizes its systemic, non-viral Oncoprex® Delivery System which
encapsulates the gene-expressing plasmids using lipid-based
nanoparticles in a lipoplex form. The resultant product is
administered intravenously, where it is taken up by tumor cells
that then express tumor suppressor proteins that were deficient in
the tumor. The Company's lead product candidate, Reqorsa® Gene
Therapy (quaratusugene ozeplasmid), is being evaluated in two
clinical trials as a treatment for NSCLC and SCLC. Each of
Genprex's lung cancer clinical programs has received a Fast Track
Designation from the FDA for the treatment of that patient
population, and Genprex's SCLC program has received an FDA Orphan
Drug Designation. Genprex's diabetes gene therapy approach is
comprised of a novel infusion process that uses an AAV vector to
deliver Pdx1 and MafA genes directly to the pancreas. In models of
Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas
into functional beta-like cells, which can produce insulin but may
be distinct enough from beta cells to evade the body's immune
system. In a similar approach, GPX-002 for Type 2 diabetes, where
autoimmunity is not at play, is believed to rejuvenate and
replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by visiting
the Company Website, registering for Email
Alerts and by following Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made on the basis of the current beliefs,
expectations and assumptions of management, are not guarantees of
performance and are subject to significant risks and uncertainty.
These forward-looking statements should, therefore, be considered
in light of various important factors, including those set forth in
Genprex's reports that it files from time to time with the
Securities and Exchange Commission and which you should review,
including those statements under "Item 1A – Risk Factors" in
Genprex's Annual Report on Form 10-K for the year ended
December 31, 2023.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
REQORSA's potential as a therapeutic treatment in inhibitor
resistant lung cancer, mesothelioma and glioblastoma; Genprex's
ability to advance the clinical development, manufacturing and
commercialization of its product candidates in accordance with
projected timelines and specifications; the timing and success of
Genprex's clinical trials and regulatory approvals; the effect of
Genprex's product candidates, alone and in combination with other
therapies, on cancer and diabetes; the effects of any strategic
research and development prioritization initiatives, and any other
strategic alternatives or other efforts that Genprex takes or may
take in the future that are aimed at optimizing and re-focusing
Genprex's diabetes, oncology and/or other clinical development
programs including prioritization of resources, and the extent to
which Genprex is able to implement such efforts and initiatives
successfully to achieve the desired and intended results thereof;
Genprex's future growth and financial status, including Genprex's
ability to maintain compliance with the continued listing
requirements of The Nasdaq Capital Market and to continue as a
going concern and to obtain capital to meet its long-term liquidity
needs on acceptable terms, or at all; Genprex's commercial and
strategic partnerships, including those with its third party
vendors, suppliers and manufacturers and their ability to
successfully perform and scale up the manufacture of its product
candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor
Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-mesothelioma-and-glioblastoma-302288226.html
SOURCE Genprex, Inc.